Section 732 of the Senate’s National Defense Authorization Act would develop a regulatory pathway for the department to sign off on “emergency uses for medical products to reduce deaths and severity of injuries caused by agents of war,” the bill reads.
While lawmakers supporting the bill say this measure is crucial and long overdue, Food and Drug Administration leaders and HHS officials say creating a new pathway for approvals is dangerous and unnecessary.
The bill is in the hands of a conference committee, which could finalize the legislation’s language by the end of the week.
FDA declined Politico‘s request to comment on the legislation.
More articles on supply chain:
Amgen to lay off 200 research & development workers
Genentech to layoff 13% of workforce at California plant
Valeant sells $1B female libido unit back to original owners 2 years after acquisition
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
